Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.69 -2.0%	$1.91	$1.29 ▼ $13.07	$63.31M	-0.14	1.39 million shs	192,808 shs
INKT MiNK Therapeutics	$15.66 -10.5%	$13.60	$4.56 ▼ $76.00	$62.41M	0.33	417,064 shs	256,092 shs
INMB INmune Bio	$2.46 -4.1%	$4.09	$1.89 ▼ $11.64	$65.25M	0.97	1.58 million shs	314,350 shs
MRKR Marker Therapeutics	$1.25 -3.5%	$1.52	$0.95 ▼ $5.95	$14.08M	1.45	554,555 shs	120,841 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	+4.24%	+8.18%	-11.34%	+20.28%	-69.88%
INKT MiNK Therapeutics	+23.24%	+34.00%	-56.91%	+134.90%	+106.22%
INMB INmune Bio	+5.79%	-7.25%	+20.75%	-64.88%	-63.32%
MRKR Marker Therapeutics	+0.78%	+6.61%	-18.35%	+14.16%	-62.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	3.6519 of 5 stars	4.6	3.0	0.0	1.9	2.5	0.6
INKT MiNK Therapeutics	2.7922 of 5 stars	3.4	5.0	0.0	1.1	1.7	0.6
INMB INmune Bio	2.3185 of 5 stars	3.3	2.0	0.0	2.7	1.7	0.6
MRKR Marker Therapeutics	4.018 of 5 stars	3.8	2.0	3.9	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.17	Buy	$16.80	897.03% Upside
INKT MiNK Therapeutics	2.75	Moderate Buy	$37.50	139.51% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	649.49% Upside
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	957.56% Upside

Current Analyst Ratings Breakdown

Latest MRKR, INMB, BMEA, and INKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00
8/6/2025	BMEA Biomea Fusion	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $10.00
8/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/21/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/18/2025	INKT MiNK Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/16/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $9.00
7/15/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$35.00
7/11/2025	INKT MiNK Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.73 per share	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($4.94) per share	N/A
INMB INmune Bio	$10K	6,525.39	N/A	N/A	$1.09 per share	2.25
MRKR Marker Therapeutics	$6.59M	2.14	N/A	N/A	$1.73 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$138.43M	-$3.03	N/A	N/A	N/A	N/A	-243.95%	-140.74%	N/A
INKT MiNK Therapeutics	-$9.51M	-$2.52	N/A	N/A	N/A	N/A	N/A	-140.72%	8/14/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)
MRKR Marker Therapeutics	-$10.73M	-$1.33	N/A	N/A	N/A	-224.46%	-101.87%	-83.02%	N/A

Latest MRKR, INMB, BMEA, and INKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INKT MiNK Therapeutics	-$0.45	-$1.06	-$0.61	-$1.06	N/A	N/A
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A
5/15/2025	Q1 2025	INKT MiNK Therapeutics	-$0.61	-$0.70	-$0.09	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.68	3.68
INKT MiNK Therapeutics	N/A	0.30	0.30
INMB INmune Bio	N/A	4.20	2.64
MRKR Marker Therapeutics	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
INKT MiNK Therapeutics	2.87%
INMB INmune Bio	12.72%
MRKR Marker Therapeutics	22.39%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	18.42%
INKT MiNK Therapeutics	22.48%
INMB INmune Bio	35.70%
MRKR Marker Therapeutics	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	37.57 million	30.65 million	Optionable
INKT MiNK Therapeutics	30	3.99 million	3.09 million	No Data
INMB INmune Bio	10	26.58 million	17.09 million	Optionable
MRKR Marker Therapeutics	60	11.31 million	10.43 million	Not Optionable

MRKR, INMB, BMEA, and INKT Headlines

Recent News About These Companies

Marker Therapeutics (MRKR) Expected to Announce Quarterly Earnings on Wednesday

August 12 at 2:27 AM | americanbankingnews.com

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025 | globenewswire.com

Marker Therapeutics Insider Trading Activity | NASDAQ:MRKR | Benzinga

July 18, 2025 | benzinga.com

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

July 11, 2025 | finance.yahoo.com

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

June 17, 2025 | globenewswire.com

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025 | globenewswire.com

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025 | globenewswire.com

Arkansas Historic Preservation Program hosts National Historic Marker Weekend

April 17, 2025 | stuttgartdailyleader.comS

Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity

April 1, 2025 | markets.businessinsider.com

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

April 1, 2025 | markets.businessinsider.com

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

April 1, 2025 | globenewswire.com

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

March 31, 2025 | markets.businessinsider.com

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

March 31, 2025 | globenewswire.com

Marker Therapeutics stockholder vote clears warrant issuance

March 28, 2025 | investing.com

Marker Therapeutics initiated with a Buy at Canaccord

March 5, 2025 | markets.businessinsider.com

Canaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation

March 5, 2025 | msn.com

Marker Therapeutics, Inc. CEO Juan Vera to Present at H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 25, 2025 | quiverquant.comQ

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 25, 2025 | globenewswire.com

MRKR stock touches 52-week low at $1.61 amid market challenges

February 12, 2025 | msn.com

Brookline Capital sets $4 target on Marker Therapeutics stock

February 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, INMB, BMEA, and INKT Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.68 -0.04 (-2.03%)

Closing price 03:59 PM Eastern

Extended Trading

$1.68 0.00 (0.00%)

As of 04:10 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

MiNK Therapeutics NASDAQ:INKT

$15.66 -1.84 (-10.53%)

Closing price 03:59 PM Eastern

Extended Trading

$15.53 -0.13 (-0.81%)

As of 04:10 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

INmune Bio NASDAQ:INMB

$2.46 -0.11 (-4.10%)

Closing price 03:59 PM Eastern

Extended Trading

$2.46 +0.00 (+0.20%)

As of 04:10 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Marker Therapeutics NASDAQ:MRKR

$1.25 -0.05 (-3.49%)

Closing price 03:59 PM Eastern

Extended Trading

$1.25 +0.00 (+0.40%)

As of 04:10 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time